Pubdiz
Taipei Medical University

Pubdiz from Gene to Disease ��] ��Ʈw

A B C D E F G H I J K L M N O P Q R X Y Z



Gene Symbol
Gene NameAliasesPrevious_Symbol

APOA1

apolipoprotein A-I


Gene APOA1 gene interaction
View Neighborhood Gene

Result number fewer <<<< << < ALL > >> >>> more

MeSH term
FrequencyCondition_Probility

Animals

140.0

Cholesterol, Dietary/*administration & dosage

327.0

*Diet

41.0

Dietary Fats/*administration & dosage

56.0

Genotype

120.0

Humans

1950.0

Linkage (Genetics)

30.0

Particle Size

31.0

Quantitative Trait, Heritable

23.0

Research Support, U.S. Gov't, P.H.S.

340.0

Alcohol Drinking

32.0

Apolipoproteins/genetics

28.0

Dietary Fats/administration & dosage

22.0

Female

1160.0

Fishes

22.0

Male

1290.0

Adolescent

300.0

Apolipoproteins/blood

146.0

Apolipoproteins E/*genetics

50.0

Child

220.0

Cholesterol/blood

312.0

English Abstract

320.0

Gene Frequency

110.0

Lipids/*blood

366.0

Lipoproteins/blood

92.0

Polymerase Chain Reaction

70.0

*Polymorphism, Restriction Fragment Length

50.0

Triglycerides/blood

362.0

Adult

900.0

Body Composition

31.0

Cross-Sectional Studies

161.0

Korea/epidemiology

23.0

Middle Aged

920.0

Questionnaires

30.0

Research Support, Non-U.S. Gov't

960.0

Viral Load

20.0

Aged

550.0

Aged, 80 and over

80.0

Analysis of Variance

80.0

*Dietary Supplements

23.0

Probability

20.0

Risk Assessment

20.0

Sensitivity and Specificity

70.0

Enzyme-Linked Immunosorbent Assay

20.0

Lipoproteins, LDL/*blood

42.0

Regression Analysis

100.0

Lipids/*metabolism

62.0

Mice

60.0

Apolipoproteins A/blood

57.0

Apolipoproteins B/*blood

85.0

Cohort Studies

80.0

Comparative Study

350.0

Lipids/blood

132.0

Reference Values

70.0

Child, Preschool

50.0

Pilot Projects

20.0

Prospective Studies

80.0

Risk Factors

330.0

Double-Blind Method

90.0

Lipoproteins, LDL Cholesterol/blood

264.0

Peritoneal Dialysis, Continuous Ambulatory

24.0

Treatment Outcome

60.0

Alleles

130.0

Alu Elements/*genetics

26.0

*Polymorphism, Genetic

140.0

Russia

22.0

Age Distribution

30.0

Dietary Fats/*pharmacology

46.0

Energy Intake

31.0

Lipoproteins, HDL Cholesterol/*blood

104.0

Polymorphism, Genetic

80.0

Population Surveillance

31.0

Research Support, U.S. Gov't, Non-P.H.S.

100.0

Sex Distribution

31.0

Apolipoprotein A-I/metabolism

56.0

Cells, Cultured

30.0

Cholesterol/*metabolism

31.0

Base Sequence

120.0

Case-Control Studies

80.0

*Glycoproteins

40.0

Molecular Sequence Data

140.0

Prevalence

60.0

Taiwan/epidemiology

32.0

Variation (Genetics)

30.0

Apolipoproteins/*blood

159.0

Lipoproteins/*blood

233.0

Apolipoprotein A-I/*blood

618.0

Body Mass Index

121.0

Retrospective Studies

50.0

Testosterone/*blood

20.0

Apolipoprotein A-I/blood

1412.0

Apolipoproteins B/blood

155.0

Greece

22.0

Lipoprotein(a)/blood

710.0

*Genetic Markers

41.0

C-Reactive Protein/*metabolism

20.0

Lipoproteins, LDL Cholesterol/*blood

33.0

Diagnosis, Differential

50.0

Lipoproteins, HDL/blood

41.0

Apolipoproteins/*genetics

34.0

Diet

30.0

Genetic Predisposition to Disease

50.0

Postprandial Period

22.0

*Alleles

20.0

ATP-Binding Cassette Transporters/*genetics

41.0

Anticholesteremic Agents/therapeutic use

26.0

Lipoproteins, HDL Cholesterol/blood

304.0

Phenotype

80.0

Promoter Regions (Genetics)/*genetics

20.0

Severity of Illness Index

30.0

Blood Pressure

50.0

Linear Models

20.0

Multivariate Analysis

30.0

Sex Factors

40.0

Skinfold Thickness

22.0

Insulin Resistance

21.0

Apolipoprotein A-I/*genetics

827.0

DNA Primers

20.0

Infant, Newborn

40.0

Lipoprotein(a)/*blood

55.0

*Promoter Regions (Genetics)

30.0

Singapore

24.0

*Variation (Genetics)

40.0

Lipoproteins, LDL/blood

41.0

Glucose Clamp Technique

21.0

Insulin Resistance/*physiology

22.0

Lipoproteins, LDL/*chemistry

29.0

Blood Glucose/metabolism

50.0

*Body Mass Index

22.0

Time Factors

120.0

Apolipoproteins A/blood/*genetics

216.0

Pedigree

50.0

Lipoproteins/*blood/chemistry

216.0

Lipoproteins, VLDL/blood

20.0

*Magnetic Resonance Spectroscopy

24.0

Asian Continental Ancestry Group/genetics

20.0

Polymorphism, Genetic/*genetics

20.0

Promoter Regions (Genetics)/genetics

20.0

Sequence Analysis, DNA

30.0

Antilipemic Agents/*therapeutic use

79.0

Coronary Disease/*blood

23.0

Drug Therapy, Combination

30.0

Simvastatin/*therapeutic use

313.0

Chromosome Mapping

30.0

Triglycerides/*blood

51.0

Administration, Oral

20.0

Follow-Up Studies

30.0

Age Factors

30.0

*Anthropometry

26.0

Body Weight

40.0

Mice, Inbred C57BL

20.0

Mice, Knockout

30.0

Rats

40.0

Rats, Sprague-Dawley

20.0

Fibrinogen/*metabolism

22.0

Chromosomes, Human, Pair 11/*genetics

20.0

Cloning, Molecular

20.0

Family Health

40.0

Heterozygote

20.0

Syndrome

30.0

Insulin/blood

40.0

Leptin/blood

23.0

Cholesterol/*blood

41.0

Fish Oils/*pharmacology

220.0

Rats, Wistar

20.0

*Blood Component Removal

26.0

Predictive Value of Tests

50.0

Apolipoproteins C/genetics

25.0

Apolipoproteins E/genetics

20.0

Cross-Over Studies

20.0

Fatty Acids/blood

24.0

Oxidation-Reduction

30.0

Phospholipids/blood

53.0

Drugs, Chinese Herbal/*therapeutic use

22.0

Apolipoprotein A-I/genetics

315.0

Apolipoproteins A/analysis

233.0

Apolipoproteins C/blood

310.0

Chromatography, Gel

20.0

Smoking

41.0

Fluorescent Antibody Technique

20.0

Microscopy, Electron

20.0

Triglycerides/metabolism

21.0

Asia

22.0

Coronary Angiography

31.0

DNA/analysis

40.0

Mutation/*genetics

20.0

Polymorphism, Single-Stranded Conformational

20.0

Amino Acid Substitution/genetics

20.0

Blood Glucose/analysis

40.0

Exercise

21.0

Amino Acid Sequence

30.0

*Micelles

220.0

Glucose Tolerance Test

20.0

Sex Characteristics

71.0

Infant

20.0

Nutritional Status

21.0

Lipids/*blood/classification

250.0

Dose-Response Relationship, Drug

40.0

Obesity

23.0

Anthropometry

20.0

DNA Mutational Analysis

30.0

Biological Markers/blood

50.0

Creatinine/blood

41.0

*Peritoneal Dialysis, Continuous Ambulatory

21.0

Serum Albumin/metabolism

21.0

Uremia/blood

211.0

Models, Genetic

20.0

Arteriosclerosis/blood

28.0

Haplotypes/*genetics

31.0

Polymorphism, Restriction Fragment Length

20.0

Lipids/blood/*metabolism

211.0

Apolipoproteins E/*blood

23.0

Chi-Square Distribution

20.0

Apolipoprotein A-I/blood/*genetics

222.0

Haplotypes

40.0

Patient Compliance

21.0

Mutation

30.0

Creatine Kinase/blood

21.0

Smoking/blood

37.0

Cell Line

30.0

RNA, Messenger/genetics

20.0

Apolipoproteins C/*genetics

55.0

Pregnancy

20.0

HIV Infections/*blood

24.0

Serum Albumin/analysis

21.0

Diabetes Mellitus, Type 2/*complications

25.0

Protein Binding

20.0

Apolipoproteins A/*genetics

510.0

Linkage Disequilibrium

50.0

*Multigene Family

20.0

*Polymorphism, Single Nucleotide

20.0

Risk

20.0

Magnetic Resonance Spectroscopy

20.0

Lipoproteins, HDL Cholesterol/metabolism

24.0

gamma-Glutamyltransferase/blood

24.0

Apolipoprotein A-I/analysis

315.0

Apolipoproteins B/analysis

310.0

Cardiovascular Diseases/*blood/epidemiology

225.0

Fatty Acids, Nonesterified/blood

21.0

Hemoglobin A, Glycosylated/metabolism

21.0

Molecular Weight

20.0

Albuminuria

24.0

Fibrinogen/analysis

21.0

Lipoproteins, VLDL Cholesterol/blood

23.0

Kinetics

20.0

Temperature

20.0

Apolipoprotein A-I

87.0

Apolipoproteins A/*chemistry

250.0

Electron Spin Resonance Spectroscopy

20.0

Dietary Proteins/*administration & dosage

27.0

*Exercise Therapy

27.0

Blotting, Southern

20.0

*Chromosomes, Human, Pair 11

30.0

Acute Disease

20.0

Statistics

20.0

Down-Regulation

20.0

Recombination, Genetic

20.0

Apolipoproteins A/*blood

24.0

Obesity/*blood

22.0